adenine has been researched along with cx 4945 in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Burke, RT; Druker, BJ; Loriaux, MM; Prins, RC; Spurgeon, SE; Tyner, JW | 1 |
Choi, CM; Choi, YJ; Hwang, DW; Kim, SC; Kim, SW; Lee, JC; Lee, YJ; Park, KM; Rho, JK; So, KS | 1 |
Casellato, A; Macaccaro, P; Mandato, E; Nunes, SC; Piazza, F; Semenzato, G; Trentin, L; Tubi, LQ; Visentin, A; Zaffino, F | 1 |
3 other study(ies) available for adenine and cx 4945
Article | Year |
---|---|
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
Topics: Adenine; Antineoplastic Agents; Casein Kinase II; Drug Synergism; Hematologic Neoplasms; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthyridines; Phenazines; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Vidarabine | 2013 |
Autophagy Induced by CX-4945, a Casein Kinase 2 Inhibitor, Enhances Apoptosis in Pancreatic Cancer Cell Lines.
Topics: Adenine; Apoptosis; Autophagy; Casein Kinase II; Cell Cycle; Cell Line, Tumor; Cell Survival; G2 Phase Cell Cycle Checkpoints; Humans; Naphthyridines; Pancreatic Neoplasms; Phenazines; RNA Interference | 2017 |
CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
Topics: Adenine; Aminopyridines; Apoptosis; Casein Kinase II; Cell Proliferation; Drug Synergism; Humans; Lymphoma, Large B-Cell, Diffuse; Morpholines; Naphthyridines; Oxazines; Phenazines; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Receptors, Antigen, B-Cell; Tumor Cells, Cultured | 2018 |